

**ABSTRACT OF THE DISCLOSURE**

Method for treating a patient in need of therapy for a neurodegenerative disease by administering to that patient a therapeutically effective dose of a triglyceride oil containing both  $\gamma$ -linolenic acid and linolenic acid residues as triglyceride ester. The ratio of  $\gamma$ -linolenic acid to linolenic acid residues at the sn-2 position of the triglyceride is at least 0.8. The amount of  $\gamma$ -linolenic acid residues at the sn-2 position is at least 18 %. The oil is administered at a dose sufficient to maintain or elevate TGF- $\beta$ 1 levels in the patient at a therapeutic level.